How do triallists decide the two key features of a trial: which patients and what endpoints? And what is the future for SGLT2 inhibitors in…
Prominent Cardiologists Decry Tepid Support For Empagliflozin By Endocrinologists
At the FDA advisory panel empagliflozin enjoyed strong support from the cardiologists and statisticians but not from the endocrinologists. An FDA advisory panel last…
Empagliflozin May Be Poised To Gain CV Indication
–FDA reviewers have raised no major questions ahead of Tuesday’s advisory panel meeting. The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will likely lend its…
Time For Cardiologists To Start Prescribing Diabetes Drugs?
There’s an emerging consensus that now may be the time for cardiologists to start thinking seriously about prescribing diabetes drugs. Until now most cardiologists have…
Companies Plan To Study Diabetes Drug In Heart Failure Population
–New attention paid to the intersection of heart failure and diabetes Boehringer Ingelheim and Eli Lilly announced on Wednesday that they were planning two separate…
Wow! Maybe– Finally– A Positive Diabetes Drug Outcomes Trial
Until now the best thing anyone could say for sure about all the new diabetes drugs was that at least they didn’t kill people. That’s…